Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study

Anticancer Research

Volumn 17, Issue 6 D, 1997, Pages 4755-4758

  Gridelli, C ^a   Rossi, A ^a   Scognamiglio, F ^a   Guida, C ^a   Fiore, F ^a   Gatani, T ^a   Scoppa, G ^a   Pergola, M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Carboplatin; Chemotherapy; Elderly patients; Non small cell lung cancer; Oral etoposide

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG CAPSULE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PATIENT SELECTION; SURVIVAL RATE;

EID: 0031427018     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Silverberg E: Cancer Statics. CA J 38: 5-22, 1988.
2. Schultz H, Gundersen S, Arnold A, Keizer J, Martin A, Canetta R: Phase II trial of carboplatin in non small cell lung carcinoma (NSCLC). Ann Oncol 1 (suppl): 60, 1990.
3. Gatzmeier U, Heckmayr M, Hossfeld DH, Zschaber R, Achterrath W, Lenaz L Phase II study of carboplatin in untreated, inoperable non small cell lung cancer. Cancer Chemother Pharmacol 26: 369-372, 1990.
4. Klastersky J, Sculier JP, Dabonig G, Bureau G, Libert P, Ravez P, Vandermoten G, Thiriaux J, Lecomte J, Cordier R, Finet C, Paesmans M, Mommen P: A randomized trial of two platinum combinations in patients with advanced non small cell lung cancer: a preliminary report. Sem Oncol 17 (suppl. 2): 20-24, 1990.
5. Evans WK, Radwi A, Tomiak E, I ogan DM, Martins H, Stewart DJ, Goss &, Marroun JA, Dahronge S: Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol 18: 149-155, 1995.
6. Matsui K, Masuda N, Takada M, Kusumoki Y, Yana T, Hirashima T, Kawasa I, Kudoh S, Furuse K, Kawahara M, Negoro S, Fukuoka M: Phase II trial of carboplatin (CBDCA) plus oral etoposide (ETP) for elderly patients with small cell lung cancer (SCI,C). Proc Am Soc Clin Oncol 1 5: 385, 1996.
7. Saxman S, Logie K, Stephens D: Phase II trial of daily oral etoposide in patients with surgical unresectable non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 9: 238, 1990.
8. Waits TM, Hainsworth JD, Johnson DH: Prolonged administration of oral etoposide in previously untreated patients with non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 10: 256, 1991.
9. Rivero O, Guzman Machado G, Rosembrock C, Cutuli D, Matwiejuk M, Triguboff E, Torchinski J, Marantz A, Gildeza E, Reale M: Phase II study: chronic oral etoposide (COE) in patients with advanced non small cell lllnsJ cancer (NSCLC). Proc Am Soc Clin Oncol 15: 393, 1996.
10. Johnson DH, Hainsworth JD, Devore R, Hande KR, Greco FA: Carboplatin plus oral etoposide in the management of unresectable non small cell lung cancer. Preliminary results of a Vanderblit trial. Oncology 49 (suppl. 1): 5761, 1992.
11. Hirobayashi M, Tomaka Y, Yoshida H, Nakagowa M, Kuno K: Treatment of unresectable non small cell lung cancer (NSCLC) with carboplatin and chronic daily administration of oral etoposide. Gan To Kaganu Ryoho 21: 53-58, 1994.
12. Gehan EA: The determination of the number of the patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346-353, 1961.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
14. Kaplan EL, Meier P: Non parametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481, 1958.
15. Salvati F, Antilli A, Cruciani AR. Lombardi A, Mugnaini L, Nunziati F, Perrone N, Portalone L, Signora M: Lonidamine plus cyclophosphamide in the treatment of advanced non small cell lung cancer in the elderly: a phase II study. Tumori 81: 48-51, 1995.
16. Gallotti P, Chiesa E, Olgiati A, Bottaro G, Natale G, Freddi E: Vindesine as monochemotherapy in non small cell lung cancer (NSCLC) in elderly patients. Ann Oncol 3 (suppl. 5): 36, 1992.
17. Malarme M, Marcelis L, Kalas JP, Bremez D Feremans W: Ifosfamide (IFO) and vindesine (VDS) therapy for non small cell lung cancer (NSCLC) in the elderly. Ann Oncol 3 (suppl. 5): 36, 1992.
18. Portalone L, D'Aprile M, De Marinis F, Contu A, Giordano F, Rinaldi M, Romano F, Belli M, Altavilla G, De Cataldis G, Addamo GF, Migliorino MR, Orto S, Bruzzi P, Salvati F, Rosso R: Management of chemotherapy in elderly patients with advanced non small cell lung cancer (NSCLC): a phase III randomized trial. Lung Cancer 11 (suppl. 1): 110, 1994.
19. Baldini E, Tibaldi C, Pfanner E, Ricci S, Falcone A, Ceribelli A, Sarcina R, Comella G, Galo Stampino C, Conte PF: Phase II study of oral doxifluridine in elderly patients with advanced non small cell lung cancer. Am J Clin Oncol 19: 592-594, 1996.
20. Rosso R, Martin C: Effect of patient age on gemcitabine toxicity profile and efficacy in advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 13: 366, 1994.
21. Sheperd F, Iglesias JL: Single agent gemcitabine: a new alternative for the treatment of elderly patients with advanced non small cell lung cancer (NSCLC). Ann Oncol 7 (suppl. 5): 43, 1996.
22. Veronesi A, Crivellari D, Magri MD, Cartei G, Mansutti M, Foladore S, Monfardini S: Vinorelbine treatment of advanced non small cell lung cancer with special emphasis on elderly patients. Eur J Cancer 32A: 1809-1811, 1996.
23. Colleoni M, Gaion F, Nelli P, Colmellere GM, Manente P: Weekly vinorelbine in elderly patients with non small cell lung cancer. Tumori 80: 448-452, 1994.
24. Gridelli C, Perrone F, Gallo C, De Marinis F, Ianniello G, Cigolari S, Cariello S, Di Costanzo F, D'Aprile M, Rossi A, Migliorino R, Bartolucci R, Bianco AR, Pergola M, Monfardini S: Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non small cell lung cancer. A two-stage phase II study. Eur J Cancer 33: 392-397, 1997.